NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

e❌wannabe,

Thanks for continuing to share your free advice and x-ceptional x-pertise 😶

Multiple novel patent-fortified dendritic cell technology platforms that are in-licensed to NWBO are in clinical trials TODAY and patients are being treated TODAY. The fact that NWBO does not need to sponsor or fund those trials is a major win for several reasons:

✅️ No cost (or very minimal cost) to the company
✅️ Independent scientific validation by peer-reviewed grants
✅️ U.S. government agency investment/buy-in



Fact ✅️: Merck is one of the supporting collaborators for the UCLA combo with pembrolizumab.

Combos with commercialized agents such as checkpoint inhibitors represent a relatively recent development—those studies have reached PII as of 2025. Undoubtedly, more combo trials are coming, potentially funded by NWBO and/or industry partner(s). However, it is misleading to suggest that there are “no active trials” today involving the DC technology platforms owned by the company. NWBO’s platforms have been under continuous clinical development for many years, and we have now entered an exciting new stage of COMBO research. Another super exciting development is the recent addition of technology created by Roswell Park!

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

NWBO 10-Q

NICE UK 🇬🇧 DCVax-L

ASM June 29, 2024

Manufacturing Technology























AI Fact-Checking